Targeting cancer therapy using oncolytic viruses
Oncolytic adenoviruses replicate and amplify themselves within tumour cells, mediating targeted cytotoxicity as well as allowing tumour-selective expression of encoded biologics such as cytokines or checkpoint inhibitor antibodies, for secretion into the tumour microenvironment. We have developed adenoviruses suitable for i.v. delivery to disseminated disease in humans, and are now ‘arming’ them to express bispecific T cell engagers (BiTEs) capable of activating endogenous T cells to attack endogenous tumour cells. This new generation of viruses can combine targeted cytotoxicity, local reversal of immune suppression and intratumoural activation of T cells to give a combined therapeutic effect that can be rapidly translated into the clinic.
Date:
23 November 2017, 11:00 (Thursday, 7th week, Michaelmas 2017)
Venue:
NDM Building, Headington OX3 7FZ
Venue Details:
TDI, Basement meeting room, NDM Research Building
Speaker:
Prof Len Seymour (Department of Oncology, University of Oxford)
Organising department:
Ludwig Institute for Cancer Research, Oxford Branch
Organiser:
Christina Woodward (Oxford Ludwig Institute, Nuffield Department of Medicine, University of Oxford)
Organiser contact email address:
christina.woodward@ludwig.ox.ac.uk
Host:
Prof Xin Lu (Ludwig Cancer Research, Oxford Branch)
Part of:
Ludwig Institute Seminar Series
Booking required?:
Not required
Audience:
Members of the University only
Editors:
Mary Muers,
Christina Woodward
